Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th American Society of Hematology Annual Meeting Received ...

Also, at ACR Convergence 2024, positive preclinical data were presented from Nurix's collaboration with Gilead to develop GS-6791/NX-0479, an IRAK4 degrader, that has potential applications in the ...

GS-6791 (previously NX-0479): GS-6791 is a potent, selective, oral degrader of IRAK4. Degradation of IRAK4 by GS-6791 has potential applications in the treatment of rheumatoid arthritis and other ...

GS-6791 (previously NX-0479): GS-6791 is a potent, selective, oral degrader of IRAK4. Degradation of IRAK4 by GS-6791 has potential applications in the treatment of rheumatoid arthritis and other ...

Sanofi's participation at the JP Morgan 43rd Annual Healthcare Conference on 14 January 2025 was marked by a comprehensive overview of the company's position in 2024 and its strategic vision for ...

Sanofi has high hopes for two asthma candidates – TSLP-targeting lunsekimig and oral BTK inhibitor rilzabrutinib – along with an anti-TL1A drug for inflammatory bowel disease, an IRAK4 ...

Got a tip? Send it to The Daily Beast here. ADVERTISEMENT ADVERTISEMENT ...

On Monday, the makers of Vicky Kaushal's Chhaava released four new powerful avatars of the actor from the film. Alongside the posters, they also announced that the trailer of the film will release on ...

Within the AD field, Sanofi has been developing the IRAK4 degrader SAR444656 (KT-474) in collaboration with Kymera Therapeutics. The drug is currently in Phase II clinical trials and may play an ...

1Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Bronx, New York.

aPsoriasis Research and Treatment Center, Department of Dermatology, Venereology and Allergology and Institute of Medical Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie ...